Business Review for the Nine Months Ended September 30, 201422 October, 2014
Solid growth in nine-month sales:
- Up 7.4%, including BioFire and at constant exchange rates
- Up 3.5% at constant exchange rates and scope of consolidation, in line with the full-year target
The Americas: a significant contribution to the Group's sales performance
- Up 7.1% at constant exchange rates and scope of consolidation
China: third-quarter acceleration in clinical application sales
2014 organic sales growth objective maintained
New platform acquired for industrial applications
“In the nine months ended September 30, 2014, bioMérieux’s sales grew by 7.4% at constant exchange rates and by 3.5% at constant exchange rates and scope of consolidation,” said Chief Executive Officer Alexandre Mérieux. “In line with our full-year target, our sales performance reflects our effectively balanced geographic positions and product portfolio. In addition, during the third quarter, we made further progress on the BioFire integration and launched innovative diagnostic solutions. Our solid growth momentum, combined with our Company’s stronger fundamentals, allows us to confirm that we are maintaining our organic sales growth objective for 2014.”
Marcy l'Etoile, France - October 22, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2014.
In the first nine months of 2014, bioMérieux’s revenue increased by 7.4% at constant exchange rates, including €45 million in sales from BioFire as from January 16, 2014. Organic growth (at constant exchange rates and scope of consolidation) came to 3.5%. Exchange rate fluctuations, primarily reflecting the rise in the euro against other currencies, resulted in a negative currency effect of €37 million, or 320 bps. In this environment, net sales for the period amounted to €1,193 million, up a reported 4.2% from €1,144 million in the first nine months of 2013.